New global data overwhelmingly suggest that a pill to prevent HIV, approved by the United States’ Food and Drug Administration in July 2012, is safer and more effective than the medical community originally thought. Importantly, new models predict that when taken daily, the drug, called Truvada, can lower the risk of HIV transmission by 99 percent. Recent studies also show that a large-scale rollout of Truvada is unlikely to lead to increased antiviral drug resistance or risk-taking behavior, as some had feared.
But old concerns, even as they have been called into question, persist, and are hindering Truvada from being widely used for HIV prevention. This needs to change.